Get started
TransMedics Group, Inc.TransMedics Group, Inc.TransMedics Group, Inc.

TransMedics Group, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

TMDX chart


Full chart

Key facts today

TransMedics Group, Inc. (TMDX) received a 'Buy' rating from Canaccord Genuity, with a target of $104. Piper Sandler maintains an Overweight rating, lowering its target to $110.
Analyze the impactAnalyze the impact

TMDX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪2.59 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
88.84
Basic EPS (TTM)
0.99 USD
Net income (FY)
‪−25.03 M‬ USD
Revenue (FY)
‪241.62 M‬ USD
Shares float
‪32.44 M‬
Beta (1Y)
1.82

Employees


Employees (FY)
584
Change (1Y)
+372 +175.47%
Revenue / Employee (1Y)
‪413.74 K‬ USD
Net income / Employee (1Y)
‪−42.86 K‬ USD

About TransMedics Group, Inc.


Sector
Health Technology
Industry
Medical Specialties
CEO
Waleed H. Hassanein
Website
transmedics.com
Headquarters
Andover
Founded
1998
FIGI
BBG00NZ6J685
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

TMDX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

TMDX highest yielding bonds


TMDX5812024
TransMedics Group, Inc. 1.5% 01-JUN-2028
Yield to maturity
−2.10%
Maturity date
Jun 1, 2028

Explore more bonds 

Frequently Asked Questions


The current price of TMDX is 77.20 USD — it has decreased by −6.90% in the past 24 hours. Watch TransMedics Group, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange TransMedics Group, Inc. stocks are traded under the ticker TMDX.
TMDX stock has fallen by −16.93% compared to the previous week, the month change is a −39.02% fall, over the last year TransMedics Group, Inc. has showed a 10.82% increase.
We've gathered analysts' opinions on TransMedics Group, Inc. future price: according to them, TMDX price has a max estimate of 179.00 USD and a min estimate of 87.00 USD. Watch TMDX chart and read a more detailed TransMedics Group, Inc. stock forecast: see what analysts think of TransMedics Group, Inc. and suggest that you do with its stocks.
TMDX reached its all-time high on Aug 23, 2024 with the price of 177.37 USD, and its all-time low was 10.00 USD and was reached on Feb 24, 2022. View more price dynamics on TMDX chart.
See other stocks reaching their highest and lowest prices.
TMDX stock is 9.68% volatile and has beta coefficient of 1.82. Track TransMedics Group, Inc. stock price on the chart and check out the list of the most volatile stocks — is TransMedics Group, Inc. there?
Today TransMedics Group, Inc. has the market capitalization of ‪2.59 B‬, it has decreased by −10.58% over the last week.
Yes, you can track TransMedics Group, Inc. financials in yearly and quarterly reports right on TradingView.
TransMedics Group, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
TMDX earnings for the last quarter are 0.12 USD per share, whereas the estimation was 0.29 USD resulting in a −59.10% surprise. The estimated earnings for the next quarter are 0.17 USD per share. See more details about TransMedics Group, Inc. earnings.
TransMedics Group, Inc. revenue for the last quarter amounts to ‪108.76 M‬ USD, despite the estimated figure of ‪115.00 M‬ USD. In the next quarter, revenue is expected to reach ‪112.22 M‬ USD.
TMDX net income for the last quarter is ‪4.22 M‬ USD, while the quarter before that showed ‪12.19 M‬ USD of net income which accounts for −65.43% change. Track more TransMedics Group, Inc. financial stats to get the full picture.
No, TMDX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 21, 2024, the company has 584.00 employees. See our rating of the largest employees — is TransMedics Group, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TransMedics Group, Inc. EBITDA is ‪49.34 M‬ USD, and current EBITDA margin is 3.63%. See more stats in TransMedics Group, Inc. financial statements.
Like other stocks, TMDX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TransMedics Group, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So TransMedics Group, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating TransMedics Group, Inc. stock shows the sell signal. See more of TransMedics Group, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.